Yehuda Handelsman to Anticholesteremic Agents
This is a "connection" page, showing publications Yehuda Handelsman has written about Anticholesteremic Agents.
Connection Strength
4.940
-
Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis. J Clin Lipidol. 2025 May-Jun; 19(3):412-421.
Score: 0.913
-
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224.
Score: 0.680
-
PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. J Am Heart Assoc. 2018 06 22; 7(13).
Score: 0.581
-
The role of bile acid sequestrants in the management of type 2 diabetes mellitus: summary and future directions. Metab Syndr Relat Disord. 2010 Dec; 8 Suppl 1:S23-4.
Score: 0.344
-
Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract. 2010 Jul-Aug; 16(4):617-28.
Score: 0.334
-
Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes. Postgrad Med. 2009 Nov; 121(6):62-9.
Score: 0.319
-
The use of the bile acid sequestrant colesevelam HCl in patients with type 2 diabetes mellitus: for glucose and lipid control. Introduction. Postgrad Med. 2009 May; 121(3 Suppl 1):5-6.
Score: 0.308
-
The role of colesevelam HCl in type 2 diabetes mellitus therapy. Postgrad Med. 2009 May; 121(3 Suppl 1):19-24.
Score: 0.308
-
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. Diabetes Care. 2025 Sep 01; 48(9):1512-1516.
Score: 0.239
-
Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects. Vasc Health Risk Manag. 2020; 16:403-418.
Score: 0.170
-
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. Diabetologia. 2019 06; 62(6):948-958.
Score: 0.153
-
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017 12; 5(12):941-950.
Score: 0.138
-
Initial combination therapy with metformin plus colesevelam in drug-na?ve Hispanic patients with early type 2 diabetes. Postgrad Med. 2012 Jul; 124(4):7-13.
Score: 0.096
-
Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes. Postgrad Med. 2012 Jul; 124(4):14-20.
Score: 0.096
-
Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus? Expert Rev Clin Pharmacol. 2012 Jan; 5(1):43-54.
Score: 0.093
-
Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 Jul-Aug; 16(4):629-40.
Score: 0.084
-
Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010 May; 12(5):384-92.
Score: 0.083